Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

Phase 1

Terminated

Conditions: Advanced Cancers

Interventions: Drug: Temsirolimus
Drug: Metformin

First Posted Date: 2012-02-09

Last Posted Date: 2025-03-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT01529593

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Rituximab
Drug: PCI-32765

First Posted Date: 2012-01-30

Last Posted Date: 2019-09-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01520519

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

BiPAP-Vapotherm RCT

Phase 2

Withdrawn

Conditions: Advanced Cancers

Interventions: Device: Oxygen Delivery Devices
Behavioral: Questionnaires

First Posted Date: 2012-01-25

Last Posted Date: 2013-08-13

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01518140

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Phase 2

Terminated

Conditions: Leukemia
Lymphoma
Myeloma
Myeloproliferative Diseases

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Alemtuzumab
Procedure: Stem Cell Infusion
Drug: Tacrolimus
Drug: Methotrexate
Drug: G-CSF
Procedure: Low Dose Donor T-Cells
Procedure: High Dose Donor T-Cells

First Posted Date: 2012-01-25

Last Posted Date: 2016-03-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01518153

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Decitabine

First Posted Date: 2012-01-24

Last Posted Date: 2025-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 160

Registration Number: NCT01515527

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Breakthrough Dyspnea Fentanyl Study in Cancer Patients

Phase 1

Completed

Conditions: Advanced Cancers
Dyspnea

Interventions: Other: Placebo
Drug: Fentanyl
Other: Walking Tests
Behavioral: Questionnaires

First Posted Date: 2012-01-24

Last Posted Date: 2014-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT01515566

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

Phase 2

Active, not recruiting

Conditions: Esophageal Cancer

Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT)
Radiation: Proton Beam Therapy (PBT)
Behavioral: Questionnaires

First Posted Date: 2012-01-19

Last Posted Date: 2025-05-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 147

Registration Number: NCT01512589

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

Phase 2

Terminated

Conditions: Non-small-cell Lung Cancer

Interventions: Radiation: SBRT (stereotactic body radiotherapy)
Radiation: SBPT (stereotactic body proton therapy)

First Posted Date: 2012-01-18

Last Posted Date: 2017-12-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01511081

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ultrafiltration (Aquapheresis) in Patients With Leukemia and Severe Fluid Overload

Not Applicable

Withdrawn

Conditions: Leukemia

Interventions: Procedure: Aquapheresis
Drug: Furosemide

First Posted Date: 2012-01-11

Last Posted Date: 2013-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01508260

Lifestyle Intervention for High Risk Cancer Survivors

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Exercise Program
Behavioral: Exercise DVD
Behavioral: Survey
Behavioral: Website
Behavioral: Self-Report Assessments

First Posted Date: 2012-01-11

Last Posted Date: 2016-12-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1150

Registration Number: NCT01508273

Locations: 🇺🇸
The University of North Texas Health Science Center, Fort Worth, Texas, United States
🇺🇸
Memorial Herman Health Care System, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy